A STUDY OF HEMATOLOGICAL AND BIOCHEMICAL PARAMETERS IN ASSESSING SEVERITY IN COVID-19 PATIENTS

Background: The severity of COVID-19 could be evaluated by examining several blood parameters mainly white blood cell (WBC) count, granulocytes, platelet, and novel hemocytometric markers neutrophils to lymphocyte ratio (NLR), platelet-to-lymphocyte (PLR),lymphocyte to monocyte ratio (LMR) and biochemical parameters such as CRP,D-dimer,Serum ferritin, LFT, KFT etc. The present study has been carried out Methods and Material: on 100 RTPCR conrmed covid-19 patients over a period of one year from July 2021 to June 2022. Clinical features, investigations, and history of associated risk factors were extracted from case records.Samples were processed in Medonic M series ve part haematology analyzer.SELECTRA PRO M and ARCHITECT plus machine was used for LDH, AST, ALT,C- reactive protein (CRP),Serum creatinine and serum urea.Samples for electrolytes were processed in INNOLYTE MACHINE. The sample for D-dimer and PT INR were processed in STA SETELLITE Max haemostasis analyser. Samples for procalcitonin were processed in CARDIAMARKER HIA-1200 machine.Chi squre test was used for analyzing signicant correlation among different parameters and covid-19 severity.P value<0.05 was dened as statistically signicant for all statistical test. Statistical analysis used: Results:Retrospective observational study Among 100 RTPCR conrmed cases,40,36,20 and 4 were mild, moderate, severe and critical respectively.Total total neutrophils count signicantly raised in critical patients(p value<0.05) while absolute lymphocyte count was signicantly decreased in critical patients(p value<0.05).NLR was signicantly raised in critical patients and LMR,PLR were also signicantly related to disease severity.CRP,S.ferritin and D- dimer were signicantly raised in critical patients(p value<0.05).Besides above parameters, Serum LDH,Serum electrolytes,AST,AL,.PT-INR were also raised in critically ill patients(p value<0.05). The severity of COVID-19 can Conclusions: be identied at an early stage by following the different routine biochemical marker levels and subsequently improve prognosis.parameters

Urgencia pediátrica: la primera línea de atención hospitalaria del paciente pediátrico con virus SARS-COV-2: el desafío que tenemos / Emergency room: the first line in the hospital medical attention of the pediatric patient with SARS-COV-2 virus: the challenge we have

The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has posed great challenges for both public health and medical clinical practice since the first cases reported in Wuhan, China. Coronavirus disease (CoVID-19) is a zoonotic disease caused by an RNA virus. SARS-CoV-2 is transmitted through respiratory droplets and fomites, and it has a lethality estimated at 4%. In the pediatric population it mainly produces mild cases, but it also can cause severe cases with hypoxemia, respiratory distress, and multiple organ failure. Children have been recognized as an important disease vector than can spread disease to higher risk groups. It is fundamental to rearrange emergency department functioning, in order to achieve an adequate patient flow that reduces the risk of disease transmission. In the following, we lay out the recommendations for patient care in the emergency room.

La emergencia mundial del virus SARS-CoV-2 (CoV2) ha producido grandes desafíos para la salud pública y para la atención clínica, desde la aparición de los primeros casos en Wuhan, China. La enfermedad, CoVID-19, es una infección zoonótica producida por un virus RNA (1). Se transmite a través de gotitas y fómites con una letalidad estimada en 4%. En pediatría, provoca cuadros respiratorios en su mayoría leves, pero también cuadros severos con hipoxemia y distrés respiratorio (2). Se ha reconocido al niño como un vector importante que aumenta los contagios en personas que tendrán probablemente cuadros de gravedad. La organización adecuada de los servicios de urgencias es fundamental para lograr un flujo y áreas especiales para los pacientes sospechosos de CoVID-19 y así evitar nuevos contagios. A continuación, se detallan las principales recomendaciones para la atención de estos pacientes en un servicio de urgencias.

Efecto de los Corticoides Parenterales en la Mortalidad por Covid-19 Severo / Effect of Parenteral Corticosteroids in Mortality from Severe Covid-19

Introducción. La infección causada por el SARS-CoV-2 puede producir un cuadro inflamatorio severo, sepsis, falla respiratoria, disfunción orgánica, y muerte. Es plausible fisiopatológicamente, que los corticoides sean una opción terapéutica razonable para Covid-19. Sin embargo, la evidencia del efecto benéfico de los corticoides sobre la mortalidad no es categórica. Objetivo: determinar si existe evidencia que avale el uso de corticoides parenterales en Covid-19 grave y Síndrome de Distrés Respiratorio Agudo (SDRA). Material y método: Este estudio se desarrolló en concordancia con la guía PRIMA. Según la estrategia PICO, nuestra Población fueron los pacientes con Covid-19 grave y/o SRDA; la Intervención, el uso de corticoides parenterales; el Comparador, los pacientes con Covid-19 severo con tratamiento estándar (sin corticoides); y el Outcome, la mortalidad y otros resultados clínicos. La búsqueda se realizó en las bases de datos PubMed, Medline, Cochrane, Embase, y LILACS usando los términos relacionados con nuestra pregunta PICO, entre el de 01 enero al 31 de agosto del 2020. Se logró recopilar un total de 287 artículos, de los que finalmente se seleccionaron 9 que cumplieron con los criterios PICO y de selección. Resultados: Según nuestro estudio, los corticoides parenterales reducen la mortalidad en pacientes con Covid-19 severo y SRDA[OR 0.83 (IC 95% 0.63-1.08)]. Conclusión: la revisión sistemática muestra que los corticoides parenterales podrían disminuir la mortalidad de pacientes con Covid-19 severo y ARDS.

Introduction. Infections caused by SARS-CoV-2 may produce a severe inflammatory response,sepsis, respiratory failure, organ dysfunction, and death. From a pathophysiological point of view, it is plausible that glucocorticoids could be a reasonable therapeutic option for Covid-19. However, the evidence supporting the benefit of corticosteroids on mortality and other clinical outcomes is no tconclusive. Objective: determinate if there exist evidence supporting corticosteroids therapy in patients with severe Covid-19 and Acute Respiratory Distress Syndrome (ARDS). Material and method: This study was performed in concordance with PRISMA guidelines. According to the PICO strategy, Population were patients with severe Covid-19 and/or ARDS; Intervention, parenteral corticosteroid administration; Comparator, patients with severe Covid-19 and/or ARDS with standard treatment (without corticosteroids); and Outcome, mortality and other clinical outcomes. Search strategy was performed in the data bases PubMed, Medline, Cochrane, Embase, and LILACS, using terms related with the PICO question; from January 1 to august 31 (2020). A total of 287 articles were initially retrieved. Of these, we finally selected only 9 article which fulfilled with PICO and selection criteria. Results: According to our study, parenteral corticosteroids reduce mortality in patients with Severe Covid-19 and/or ARDS [OR 0.83 (IC 95% 0.63-1.08)]. Conclusion: the systematic review shows that parenteral corticosteroids could reduce the mortality of patients with severe Covid-19 and ARDS.